SecSonar.com

Iovance Biotherapeutics, Inc. (IOVA)

Iovance Biotherapeutics, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Iovance Biotherapeutics, Inc. (IOVA) is a Biotechnology company based in US with a market capitalization of $1.4B. Revenue grew 60.6% year-over-year and free cash flow was negative at -$336.2M. This page tracks IOVA's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 838 employees · IPO Oct 15, 2010

Valuation

Valuation & price

$3.45 · as of May 17, 2026 · -36.2% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

2.05

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$5.20$3.45$1.70Jul 25Dec 25Jul 26Jul 7, 25$1.70Jul 9, 25$1.99Jul 11, 25$1.87Jul 15, 25$1.94Jul 17, 25$2.34Jul 21, 25$2.49Jul 23, 25$3.97Jul 25, 25$3.13Jul 29, 25$2.92Jul 31, 25$2.57Aug 4, 25$2.83Aug 6, 25$2.58Aug 11, 25$1.97Aug 13, 25$2.45Aug 15, 25$2.55Aug 19, 25$2.60Aug 21, 25$2.54Aug 25, 25$2.53Aug 27, 25$2.42Aug 29, 25$2.23Sep 3, 25$2.21Sep 5, 25$2.49Sep 9, 25$2.37Sep 11, 25$2.42Sep 16, 25$2.30Sep 18, 25$2.20Sep 22, 25$2.12Sep 24, 25$2.12Sep 26, 25$2.11Sep 30, 25$2.17Oct 2, 25$2.25Oct 6, 25$2.21Oct 8, 25$2.27Oct 10, 25$2.10Oct 14, 25$2.12Oct 16, 25$2.24Oct 21, 25$2.27Oct 23, 25$2.19Oct 27, 25$2.31Oct 29, 25$2.00Oct 31, 25$1.97Nov 4, 25$1.82Nov 6, 25$2.31Nov 10, 25$2.37Nov 12, 25$2.54Nov 14, 25$2.47Nov 18, 25$2.44Nov 20, 25$2.18Nov 25, 25$2.48Nov 28, 25$2.47Dec 2, 25$2.13Dec 4, 25$2.20Dec 8, 25$2.31Dec 10, 25$2.26Dec 12, 25$2.20Dec 16, 25$2.25Dec 18, 25$2.46Dec 22, 25$2.78Dec 24, 25$2.87Dec 29, 25$2.79Jan 2, 26$2.52Jan 6, 26$2.55Jan 8, 26$2.61Jan 12, 26$2.40Jan 14, 26$2.38Jan 16, 26$2.36Jan 21, 26$2.51Jan 23, 26$2.64Jan 27, 26$2.98Jan 29, 26$2.63Feb 2, 26$2.61Feb 4, 26$2.44Feb 9, 26$2.60Feb 11, 26$2.60Feb 13, 26$2.57Feb 18, 26$2.72Feb 20, 26$2.87Feb 24, 26$3.78Feb 26, 26$3.79Mar 2, 26$3.79Mar 4, 26$4.26Mar 6, 26$5.13Mar 10, 26$5.20Mar 12, 26$4.07Mar 17, 26$3.89Mar 19, 26$3.87Mar 23, 26$3.63Mar 25, 26$3.75Mar 27, 26$3.51Mar 31, 26$3.51Apr 2, 26$3.43Apr 7, 26$3.32Apr 9, 26$4.01Apr 13, 26$3.46Apr 15, 26$3.82Apr 17, 26$3.86Apr 22, 26$3.53Apr 24, 26$3.44Apr 28, 26$3.38Apr 30, 26$3.36May 4, 26$3.85May 6, 26$4.09May 8, 26$3.62May 12, 26$3.56May 14, 26$3.52May 18, 26$3.39May 20, 26$3.54May 22, 26$4.11May 28, 26$4.30Jun 1, 26$3.96Jun 3, 26$3.79Jun 5, 26$4.23Jun 9, 26$3.88Jun 11, 26$3.96Jun 15, 26$4.03Jun 17, 26$3.93Jun 22, 26$4.06Jun 24, 26$4.25Jun 26, 26$4.25Jul 2, 26$4.31
$1.7052-week range$5.41
Loading valuation history…

Fundamentals

Key fundamentals

$1.4B

Market cap

60.6%

Revenue growth (YoY)

97.2%

Gross margin

-$336.2M

Free cash flow (USD)

-$248.5M

Net debt

Net cash position

23.3%

Share dilution

1/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$0.00FY 2017$0.00FY 2018$0.00FY 2019$0.00FY 2020$0.00FY 2021$0.00FY 2022$0.00FY 2023$1.2MFY 2024$164.1MFY 2025$263.5M
$0$263.5M

Free cash flow by year

2016 → 2025

FY 2016$-34.2MFY 2017$-79.7MFY 2018$-102.4MFY 2019$-165.8MFY 2020$-251.9MFY 2021$-265.5MFY 2022$-313.2MFY 2023$-384.1MFY 2024$-364.0MFY 2025$-336.2M
-$34.2M-$336.2M

Gross margin by year

2023 → 2025

FY 2023-804.5%FY 202424.4%FY 202597.2%
-804.5%97.2%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

0

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 7, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 8-K eventRevenue Guidance UpdateJul 2, 2026Filing
  • FinancingSecurities RegistrationJun 18, 2026Filing
  • 8-K eventAnnual Meeting ResultsJun 10, 2026Filing
  • Quarterly report10-Q FiledMay 7, 2026Filing
  • 8-K eventEarnings ReleaseMay 7, 2026Filing

Questions

Frequently asked questions

What is Iovance Biotherapeutics, Inc.'s market cap?

Iovance Biotherapeutics, Inc. (IOVA) has a market capitalization of $1.4B.

What is IOVA's P/E ratio?

A meaningful P/E ratio is not available for IOVA — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is IOVA's price-to-book (P/B) ratio?

IOVA trades at 2.05 times book value per share.

Are insiders buying IOVA stock?

SEC Form 4 filings show no open-market insider buys at Iovance Biotherapeutics, Inc. in the last 90 days (0 sells).

Same arena

Related companies in Biotechnology

FTRE

Fortrea Holdings Inc.

$1.5B

IMCR

Immunocore Holdings plc

$1.5B

TSHA

Taysha Gene Therapies, Inc.

$1.5B

MAZE

Maze Therapeutics, Inc.

$1.5B

URGN

UroGen Pharma Ltd.

$1.4B

CAPR

Capricor Therapeutics, Inc.

$1.4B

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.